4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni The Network is a Biomarker in Cancer Signatures Sol Efroni The Mina & Everard Goodman.

Slides:



Advertisements
Similar presentations
Biological pathway and systems analysis An introduction.
Advertisements

Yan Guo Assistant Professor Department of Cancer Biology Vanderbilt University USA.
Data integration across omics landscapes Bing Zhang, Ph.D. Department of Biomedical Informatics Vanderbilt University School of Medicine
MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.
Andrey Alexeyenko M edical E pidemiology and B iostatistics Network biology and cancer data integration.
Cluster analysis of networks generated through homology: automatic identification of important protein communities involved in cancer metastasis Jonsson.
Introduction Integrative Analysis of Genomic Variants in Carcinogenesis Syed Haider, Arek Kasprzyk, Pietro Lio Artificial Intelligence and Computational.
Gene Co-expression Network Analysis BMI 730 Kun Huang Department of Biomedical Informatics Ohio State University.
ONCOMINE: A Bioinformatics Infrastructure for Cancer Genomics
Systems biology in cancer research. What is systems biology? = Molecular physiology? “… physiology is the science of the mechanical, physical, and biochemical.
Andrey Alexeyenko M edical E pidemiology and B iostatistics Gene network approach in epidemiology.
27803::Systems Biology1CBS, Department of Systems Biology Schedule for the Afternoon 13:00 – 13:30ChIP-chip lecture 13:30 – 14:30Exercise 14:30 – 14:45Break.
Microarray-based Disease Prognosis using Gene Annotation Signatures Michael Kovshilovsky Swapna Annavarapu SoCalBSI 2005.
3 rd Summer School in Computational Biology September 10, 2014 Frank Emmert-Streib & Salissou Moutari Computational Biology and Machine Learning Laboratory.
1 Robust diagnosis of DLBCL from gene expression data from different laboratories DIMACS - RUTCOR Workshop on Boolean and Pseudo-Boolean Functions in Memory.
Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.
2nd Quebec Conference on Therapeutic Resistance in Cancer Bienvenue !!!!!
Stress Regulation of Tumor Biology Robert T. Croyle, PhD Director Division of Cancer Control and Population Sciences Concept Presentation NCI Board of.
Apostolos Zaravinos, Myrtani Pieri, Nikos Mourmouras, Natassa Anastasiadou, Ioanna Zouvani, Dimitris Delakas, Constantinos Deltas Department of Biological.
Radiogenomics in glioblastoma multiforme
Introduction The effects of HER2 gene and receptor over- expression on breast cancer. Prognosis and treatment of HER2+ breast cancer. (See figure 1)
Effects of siRNA mediated gene knockdown on the formation of focal adhesions Sabina Winograd-Katz, Zvi Kam and Benjamin Geiger Department of Molecular.
Head and Neck Cancer: microRNA analysis
Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.
Predicting MicroRNA Genes and Target Site using Structural and Sequence Features: Machine Learning Approach Malik Yousef Institute of Applied Research,
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
Agent-based methods for translational cancer multilevel modelling Sylvia Nagl PhD Cancer Systems Science & Biomedical Informatics UCL Cancer Institute.
Construction of cancer pathways for personalized medicine | Presented By Date Construction of cancer pathways for personalized medicine Predictive, Preventive.
Bioinformatics lectures at Rice University Li Zhang Lecture 9: Networks and integrative genomic analysis
COMPUTATIONAL ANALYSIS OF MULTILEVEL OMICS DATA FOR THE ELUCIDATION OF MOLECULAR MECHANISMS OF CANCER Presented by Azeez Ayomide Fatai Supervisor: Junaid.
Bioinformatics MEDC601 Lecture by Brad Windle Ph# Office: Massey Cancer Center, Goodwin Labs Room 319 Web site for lecture:
Chemokine mRNA expression profiling in pulmonary sarcoidosis Kriegova E, Fillerova R, Arakelyan A, Mrazek F, Hutyrova B, Kolek V, du Bois R*, Petrek M.
While gene expression data is widely available describing mRNA levels in different cancer cells lines, the molecular regulatory mechanisms responsible.
ICNCT-16, June 2014, Helsinki Glioma heterogeneity and the L-Amino acid transporter-1 (LAT1): A first step to stratified BPA-based BNCT? D. Ngoga 1 ; C.
Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.
Jin MENG Shen FU (DPD 08) Biology 2 - Head/Neck and CNS Tumors
Pan-cancer analysis of prognostic genes Jordan Anaya Omnes Res, In this study I have used publicly available clinical and.
CBioPortal Web resource for exploring, visualizing, and analyzing multidimentional cancer genomics data.
Eigengenes as biological signatures Dr. Habil Zare, PhD PI of Oncinfo Lab Assistant Professor, Department of Computer Science Texas State University 5.
Introduction to Oncomine Xiayu Stacy Huang. Oncomine is a cancer-specific microarray database and has a web-based data-mining platform aimed at facilitating.
(1) Genotype-Tissue Expression (GTEx) Largest systematic study of genetic regulation in multiple tissues to date 53 tissues, 500+ donors, 9K samples, 180M.
 We investigated for biomarkers that distinguish metastatic or recurring disease with non-metastatic disease, with a particular focus on breast cancer.
XXV^ Riunione Nazionale MITO Innovation in gynecologic cancer: optimal therapy, quality of life, precision medicine. Naples, June Targeting.
Tumor Heterogeneity: From biological concepts to computational methods Bo Li, PhD Dana Farber Cancer Institute Harvard Statistics Department.
Eigengenes as biological signatures Dr. Habil Zare, PhD PI of Oncinfo Lab Assistant Professor, Department of Computer Science Texas State University 3.
Raphael Sandaltzopoulos, PhD, MBA Professor at MBG (Molecular Biology) Lab. of Gene Expression, Molecular Diagnosis and Modern Therapeutics,
David Amar, Tom Hait, and Ron Shamir
miRNA-targets cross-talks: key players in glioblastoma multiforme
MicroRNA-34a: a key regulator in the hallmarks of renal cell carcinoma
Fig. 1 Increased MIR155HG expression correlates with glioma grade and mesenchymal transition and confers a poor prognosis in GBM patients. (A) The level.
MiR-155-5p positively regulates colon cancer cell migration by targeting RhoA 2016 Molecular Biomarkers, Berlin | AMR AL-HAIDARI | Department of Clinical.
Loyola Marymount University
Computational Discovery of miR-TF Regulatory Modules in Human Genome
Volume 17, Issue 8, Pages (November 2016)
Volume 24, Issue 12, Pages e5 (September 2018)
Single Sample Expression-Anchored Mechanisms Predict Survival in Head and Neck Cancer Yang et al Presented by Yves A. Lussier MD PhD The University.
Robust diagnosis of DLBCL from gene expression data from different laboratories DIMACS - RUTCOR Workshop on Boolean and Pseudo-Boolean Functions in Memory.
Volume 25, Issue 13, Pages e6 (December 2018)
Loyola Marymount University
DNMT3A2 signatures are coherently modified in AML.
Loyola Marymount University
Loyola Marymount University
Loyola Marymount University
Reduced BAI1 expression is associated with breast cancer patient survival. Reduced BAI1 expression is associated with breast cancer patient survival. A,
EN1 expression in breast cancer and clinical outcome.
Coexpression of other immune genes with ImSig core signatures.
The Role of TIPE2 Protein in Invasive Breast Carcinoma
Global analysis of the chemical–genetic interaction map.
Highly metastatic PDAC cells have a unique gene signature, which is not preserved in metastases but predicts poor patient outcome. Highly metastatic PDAC.
Fig. 1. FAM83H over-expression is associated with poor prognosis of CC
Presentation transcript:

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni The Network is a Biomarker in Cancer Signatures Sol Efroni The Mina & Everard Goodman Faculty of Life Sciences Bar Ilan University

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni My Lab Rep-Seq Benichou et al, Immunology 2012 Vainas et al, Autoimmunity 2011 Mascanfroni et al, Nature Immunology 2013 Cancer Genomics Systems Immunology

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni

Introduction Biomarkers Regulation Implementation Complex Biomarkers Clinically motivated multi gene markers

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni The problem with Multi-gene mRNA markers Robustness Introduction Biomarkers Regulation Implementation

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Introduction Biomarkers Regulation Implementation

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Introduction Biomarkers Regulation Implementation TCGA

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Introduction Biomarkers Regulation Implementation

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Phenotype comparison TumorNormal Introduction Biomarkers Regulation Implementation

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni TumorNormal Introduction Biomarkers Regulation Implementation Phenotype comparison

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Introduction Biomarkers Regulation Implementation A single number to represent the Pathway within this sample

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Example Regulation as metric Introduction Biomarkers Regulation Implementation

Gene 1 Gene 2 Gene 1 is a perfect biomarker Gene 2 is a perfect biomarker The pathway is enriched with the interesting genes Gene 1 and Gene 2 and and is therefore important

Gene 1 Gene ? 1 Network Gene 1 is a poor biomarker Gene 2 is a poor biomarker The two gene network is a perfect biomarker Perfect corr Perfect anti corr

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni

Introduction Biomarkers Regulation Implementation

Efroni et al IET Systems Biology 2013 Greenblum et al. BMC Bioinformatics 2011 Efroni et al PLoS ONE 2009 Introduction Biomarkers Regulation Implementation

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Pathways as biomarkers and pathways as targets in GBM and in Ovarian cancer

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Rotem Ben-HamoDr. Helit Cohen Introduction Biomarkers Regulation Implementation ovarian

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Methodology Ovarian Cancer – 511 patients, 348 whole exomes Introduction Biomarkers Regulation Implementation ovarian Data Collection

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Ovarian cancer gene signature Introduction Biomarkers Regulation Implementation ovarian

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Ben-Hamo R, Efroni S. BMC Systems Biology (2012) Survival Analysis: Gene based Introduction Biomarkers Regulation Implementation ovarian

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni A pathway view highlights a single pathway Introduction Biomarkers Regulation Implementation ovarian

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Duke1 Dataset 119 patients Duke2 Dataset 42 patients TCGA 511 patients Ovarian Cancer: PDGF Signaling Pathway provides a robust signature Introduction Biomarkers Regulation Implementation ovarian

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Again, a collection of sources for clinical and molecular data GBM Introduction Biomarkers Regulation Implementation GBM

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Pathway 1 Pathway 2 Pathway 3 Pathway 4 Pathway 5 Pathway 6 … Pathway 579 Introduction Biomarkers Regulation Implementation GBM

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni The p38 pathway is most significant “p38 signaling mediated by mapkap kinases” Introduction Biomarkers Regulation Implementation GBM

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Preliminary Results Ben-Hamo R, Efroni S. Genome Medicine (2011) Ben-Hamo R, Efroni S. Systems Biomedicine (2013) The p38 pathway is robust across multiple datasets Introduction Biomarkers Regulation Implementation GBM

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Another type of regulation has been suggested: microRNA Control over Pathways Inui M et al. Nature Reviews Molecular Cell Biology (2010) Introduction Biomarkers Regulation Implementation GBM

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Introduction Biomarkers Regulation Implementation GBM

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni hsa-miR-9 R 2 = R 2 = P38 signaling pathway P38/MAPKP Pathway AND hsa-miR-9 Introduction Biomarkers Regulation Implementation GBM

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Preliminary Results - Computational hsa-miR-9 R 2 = R 2 = P38 signaling pathway P38/MAPKP Pathway AND hsa-miR-9 Introduction Biomarkers Regulation Implementation GBM

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Preliminary Results - Experimental Expression levels of P38 pathway genes in HeLa Vs. HMEC cell lines HeLa: cervical cancer cell line. HMEC: (Human mammary epithelial cell) primary cell line. microRNAs regulation of pathways - GBM Introduction Biomarkers Regulation Implementation GBM

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Expression levels of P38 pathway genes in HeLa cell lines after miR-9 transfection microRNAs regulation of pathways - GBM Introduction Biomarkers Regulation Implementation GBM

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni miR-9 down regulation of the p38 network improves prognosis ? Can we see the same effect with drug response? Introduction Biomarkers Regulation Implementation GBM

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Drug response Patients are treated using a wide spectrum of 69 different drugs Drugs are classified into two groups: drugs that target genes in the p38 pathway And drugs that do not target genes in the pathway Introduction Biomarkers Regulation Implementation GBM

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Out of the 69 drugs given to the patients 6 drugs target genes that are part of the p38 network Drug NameTargetPathway AccutaneRARAmap kinase inactivation of smrt co-repressor CCNUSTMN4Signaling mediated by p38-gamma and p38-delta pathway CelebrexCOX2Signaling mediated by p38-alpha and p38-beta pathway Cis Retinoic AcidRARAmap kinase inactivation of smrt co-repressor SorafenibRAF1p38 signaling mediated by MAPKAP kinases TamoxifenESR1Signaling mediated by p38-alpha and p38-beta pathway Introduction Biomarkers Regulation Implementation GBM

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Group1 Low survival 169 patients Average overall survival time – 433 days Median survival time – 310 days All patients did not received p38 targeted drugs Group2 High survival 63 patients Average overall survival – 896 days Median survival time – 691 days All patients received p38 targeted drugs Ben-Hamo R, Efroni S. Genome Medicine (2011) Ben-Hamo R, Efroni S. Systems Biomedicine (2013) (CAMDA first prize)

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni

Summary Measure the Network Target the Network

4 th Conference in Quantitative Biology QUB, September 2013Sol Efroni Summary Core biology hides in functional wiring of the network By selecting for robust signatures we achieve significant markers for prognosis By following the outline of these signatures we discover biology that may lead to treatment

Acknowledgements Helit Cohen Rotem Ben Hamo Alona Zilberberg Jennifer Benichou Rivka Cashman Moriah Cohen Miri Gordin Dror Hibsh Ido Sloma Hagit Philip Renana Kozol

SYSTEMS BIOMEDICINE JOURNAL

Mechanisms